BioNTech (NASDAQ: BNTX) CEO sells 93,000 shares under preplanned deal

What happened

BioNTech SE (NASDAQ: BNTX) said Chief Executive Officer and 10% owner Ugur Sahin sold 93,000 ordinary shares over 2026-10-05 and 2026-10-06. On 2026-10-05, Sahin sold 72,000 shares at $97.2312, and on 2026-10-06, Sahin sold 21,000 shares at $96.8093. The shares fetched $96.81 to $97.23 apiece, for about $9.03 million. After the sales, Sahin held 87,209 shares directly. The filing says the trades followed a Rule 10b5-1 trading plan, and the plan was established on June 3, 2026.

Key numbers

Metric	Latest	Change	Source
Shares sold	93,000 shares		SEC Form 4
Total sale value	$9.03 million		SEC Form 4
Shares held after sale	87,209 shares		SEC Form 4
Sale price range	$96.81 to $97.23 per share		SEC Form 4
Shares sold as a share of pre-trade holding	51.6%		Calculated from SEC Form 4
Indirect ordinary shares held by Medine GmbH	39,218,111 shares		SEC Form 4

Read more: BioNTech (BNTX) stock analysis and investment case

Why it matters

OptimistFi's case is that BioNTech works only if its mRNA and immunotherapy platform becomes a durable non-COVID oncology business before vaccine cash flows and R&D losses erode option value. This filing is mixed for that view because Sahin reduced direct ownership, but the sales were preplanned rather than a spontaneous trade. The 93,000 shares were about 51.6% of the holding before the trade, so the move was a meaningful trim of the direct stake.

The filing also says 39,218,111 ordinary shares are held by Medine GmbH. Of those shares, 106,721 are held for the benefit of an individual under a trust arrangement. Medine GmbH exercises voting power, but not dispositive power, over them while they are held in trust. Sahin may be deemed to beneficially own the ordinary shares held by Medine GmbH, which limits how much investors can read into the sale.

Related: BioNTech Ends Cancer-Vaccine Trial, Raising Stakes for Oncology

What's next

The next quarterly report will be the next scheduled check on the broader story. Later ownership filings will show whether Sahin's direct stake stabilizes or keeps shrinking. A later buying filing would weaken the read that Sahin is steadily reducing direct exposure, while more planned selling would keep the signal mixed. Until then, this Form 4 is a snapshot of ownership, not an operating update. Investors get the cleanest read from whether the direct stake stops falling in later filings.

More from OptimistFi